As investors, we don't have a crystal ball. The world moves so fast that nobody knows for sure what is going to happen next week, let alone five or 10 yearsThis article was co-produced with Kody Kester.Introducing iREIT®Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.We recently added an all-new Rating ...

Core Points - Banco Comercial Português, S.A. has received a notification from Banco de Portugal regarding the Minimum Requirement for Own Funds and Eligible Liabilities (MREL) [1] Group 1 - The notification pertains to the regulatory requirements that the bank must meet in terms of capital and eligible liabilities [1] - MREL is a key component in ensuring that banks have sufficient resources to absorb losses and support resolution processes [1] - Compliance with MREL is essential for maintaining financial stability and protecting depositors [1]

Key Takeaways Moderna gained full FDA approval for Spikevax in high-risk children aged six months to 11 years. The vaccine was previously available for this group only under Emergency Use Authorization. Updated Spikevax will be available for eligible patients in the 2025-2026 U.S. vaccination season.Moderna (MRNA) announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 vaccine, Spikevax, for use in children aged six months to 11 years, who are at in ...

Group 1: Moderna's Vaccine Approval - The U.S. FDA has approved Moderna's supplemental Biologics License Application for Spikevax, allowing its COVID-19 vaccine for children aged six months to 11 years at increased risk for COVID-19 disease [1] - Moderna's CEO emphasized the importance of vaccination for protecting children against severe disease and hospitalization, expressing appreciation for the FDA's review and approval [2] - The updated Spikevax vaccine is expected to be available for eligible populations in the U.S. for the 2025-2026 respiratory virus season [2] Group 2: Legal Challenges and Patent Issues - Pfizer and BioNTech have requested a reversal of a court ruling that found their COVID-19 vaccine infringed on a Moderna patent, while a previous ruling declared one of Moderna's patents invalid [3] - The companies argue that Moderna's mRNA technology is a continuation of earlier research, questioning the validity of the patent [4] - Moderna maintains that the court's decision to uphold the patent is correct and should remain [4] Group 3: FDA's Vaccine Approval Decisions - The FDA's top vaccine official overruled agency scientists to limit the approval of two COVID-19 vaccines, despite recommendations for broader use [6] - The official restricted the vaccines to higher-risk individuals, citing declining hospitalization and death rates from COVID-19 as a factor in the decision [7] - Following the news, Moderna's stock price increased by 3.60% to $33.97 [7]

自体生成CAR-T疗法可显著降低成本，但技术壁垒极高。 传统的CAR-T细胞疗法是将人的T细胞在体外经过基因工程手段修饰改造后，回输患者体内，这已成为 治疗恶性血液肿瘤革命技术，但疗法价格昂贵，费用高达上百万元，难以大规模推广。 当前，另外一种CAR-T疗法，即自体生成CAR-T疗法正成为全球生物医药领域的新兴赛道，且有升温趋 势。 近日，全球制药巨头艾伯维宣布以21亿美元收购自体生成CAR-T细胞疗法开发商Capstan Therapeutics， 以扩大自身免疫性疾病疗法的产品线，该收购金额创下2025年细胞治疗领域最高交易纪录。 与此同时，港股上市公司云顶新耀（01952.HK）也在近日公布了公司在自体生成CAR-T领域的最新开 发进展。据介绍，公司基于自主研发的靶向LNP（tLNP）系统开发的自体生成CAR-T项目，可用于治 疗肿瘤和自身免疫性疾病，已取得多项临床前验证。在人源化小鼠肿瘤模型中，该疗法已实现有效的肿 瘤细胞清除；在非人灵长类动物（猴）模型中，也已验证T细胞的高效转染、CAR的表达以及B细胞的 清除效果。 云顶新耀首席执行官罗永庆对第一财经记者表示，自体生成CAR-T疗法相比传统CAR- ...

Yup, @Grok can do incredible ASMRAutism Capital 🧩 (@AutismCapital):WHAT HAVE THEY DONE? OH NO LMAO. ASMR GROK 😂🤦‍♂️ https://t.co/raStsW82Dd ...

RT Min Choi (@minchoi)I asked Google Veo 3 for food cooking ASMR.Results are wild1. Steak https://t.co/Z0JJYrCWWf ...

CALGARY, AB, July 9, 2025 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and MRI technology for industrial and research applications announces the publication in the National Formulary of the first regulatory certified assay for benchtop NMR – the Molar Substitution Determination in Hydroxypropyl Betadex USP-NF/Ph. Euro (1804)."Currently Nanalysis sells primarily into industrial R&D labs and universities, but to more ubiqui ...

证券代码：300812 证券简称：易天股份 编号：2025-002 深圳市易天自动化设备股份有限公司 投资者关系活动记录表 | | 特定对象调研 | | ☐分析师会议 | | --- | --- | --- | --- | | 投资者关系活动 | ☐媒体采访 | | ☐业绩说明会 | | 类别 | ☐新闻发布会 | | ☐路演活动 | | | ☐现场参观 | | | | | ☐其他电话会议 | | | | 形式 | 现场 | ☐网上 | ☐电话会议 | | 参与单位名称及 | 华福证券：卢大炜先生 | | | | 人员姓名 | 中邮基金：沈路遥先生 | | | | 时间 | 2025 年 7 月 | 9 | 日（星期三）10:00-11:30 | | 地点 | 深圳市易天自动化设备股份有限公司会议室 | | | | 上市公司接待人 | 副总经理、董事会秘书：王亚丽女士 | | | | 员姓名 | 证券事务代表：莫凤艳女士 | | | | | 一、介绍公司概况 | | | | | | | 简要介绍公司及子公司发展历程、主营业务、整体经营情况、核 | | | 心优势及未来发展规划等情况。 | | | | | ...

智通财经APP获悉，能源转型推动需求拐点到来，矿山复产将作为主要供给增量，受前10年资本开支低 迷影响，新增矿山供给有限，天然铀供需将维持紧平衡;长期看，人工智能及小型模块化反应堆(SMR) 技术爆发或支撑长期需求，现有矿山资源逐步衰减，复产产能释放完毕后，一次供给缺口或将继续扩 大，二次供给或加速消耗。 中核国际（02302）：中核国际为中核集团旗下唯一海外铀资源运作平台。2024年财报显示，公司扩大 铀贸易规模，全年销售约577万磅天然铀，总收入达18.41亿港元，同比大幅增长217%。全年净利润为 1.95亿港元，同比增长83.4%。 中信建投研报认为，双碳目标、能源安全、AI热潮之下，全球核能复苏，中美法日等核电大国竞相推 进核电项目审批及建设，叠加金融机构持续采购，铀需求势将稳中有增；铀价长期低迷，矿山资本开支 萎缩，新增矿山供给受限，现役矿山地理分布高度集中，脆弱性强；十年供需错配导致库存持续去化， 二次供给弹性下降，天然铀价格易涨难跌，第三轮牛市将长期持续。库存对铀价提供的调节作用持续下 滑，天然铀现货价格将更易受供应、需求端扰动而产生波动，但方向是易涨难跌。 天然铀相关产业港股： 中广核矿业( ...